MyFinsight
Home
Blog
About
Net proceeds from
issuance of series a...
$1,232,695
Net proceeds from
issuance of common stock
$166,700
(-81.71%↓ Y/Y)
Net cash provided by
financing activities
$951,217
(369.08%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
$2,225
(-91.44%↓ Y/Y)
Canceled cashflow
$448,178
Net change in cash,
cash equivalents and...
-$5,902,190
(44.65%↑ Y/Y)
Canceled cashflow
$953,442
Depreciation and
amortization
$572,143
(-7.45%↓ Y/Y)
Stock-based compensation
expense
$286,602
(-61.08%↓ Y/Y)
Write-off of deferred
offering costs
$268,826
Interest payable
$165,485
(-38.42%↓ Y/Y)
Right-of-use assets -
operating lease
-$131,659
(47.61%↑ Y/Y)
Accounts receivable
-$123,827
Other receivables
-$107,501
(-156.77%↓ Y/Y)
Non-cash interest
expense
$14,808
(-88.19%↓ Y/Y)
Principal payments on
financing lease
$448,178
(-2.33%↓ Y/Y)
Net cash used in
operating activities
-$6,775,046
(37.78%↑ Y/Y)
Canceled cashflow
$1,670,851
Net cash used in
investing activities
-$80,586
(-1947.93%↓ Y/Y)
Deferred grant funding
$3,195,735
(-24.54%↓ Y/Y)
Net loss
-$2,982,773
(64.47%↑ Y/Y)
Prepaid expenses
$1,005,880
(314.13%↑ Y/Y)
Accounts payable
-$392,990
(-158.41%↓ Y/Y)
Other current assets
$322,016
Other non-current
assets
$314,541
(1182.01%↑ Y/Y)
Operating lease
liabilities
-$148,444
(44.26%↑ Y/Y)
Accrued expenses
-$80,380
(79.29%↑ Y/Y)
Non-cash royalty revenue
related to sale of future...
$3,138
(-26.25%↓ Y/Y)
Purchases of property and
equipment
$80,586
(1947.93%↑ Y/Y)
Back
Back
Cash Flow
Dare Bioscience, Inc. (DARE)
Dare Bioscience, Inc. (DARE)
source: myfinsight.com